A detailed history of Invesco Ltd. transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 10,474 shares of DSGN stock, worth $33,516. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,474
Previous 10,937 4.23%
Holding current value
$33,516
Previous $28,000 50.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$2.27 - $4.03 $1,051 - $1,865
-463 Reduced 4.23%
10,474 $42,000
Q4 2023

Feb 12, 2024

BUY
$1.99 - $2.76 $21,764 - $30,186
10,937 New
10,937 $28,000
Q3 2022

Nov 14, 2022

SELL
$14.09 - $25.57 $1,113 - $2,020
-79 Reduced 0.78%
10,058 $168,000
Q2 2022

Aug 15, 2022

BUY
$9.91 - $17.33 $100,457 - $175,674
10,137 New
10,137 $142,000
Q1 2022

May 16, 2022

SELL
$11.17 - $20.89 $107,477 - $201,003
-9,622 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$13.64 - $21.41 $131,244 - $206,007
9,622 New
9,622 $206,000

Others Institutions Holding DSGN

About Design Therapeutics, Inc.


  • Ticker DSGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,807,900
  • Market Cap $179M
  • Description
  • Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...
More about DSGN
Track This Portfolio

Track Invesco Ltd. Portfolio

Follow Invesco Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.